2014-10-27 16:00Financial Performance - Operating revenue for Q3 2014 reached RMB 1,491,710,662.63, representing a 39.27% increase year-over-year[7] - Net profit attributable to shareholders was RMB 132,375,173.14, up 10.84% compared to the same period last year[7] - Basic earnings per share for Q3 2014 was RMB 0.45, reflecting a 12.50% increase year-over-year[7] - The company reported a significant increase in net profit for the third quarter of 2014, with a year-on-year growth of 12%[24] Assets and Liabilities - Total assets increased by 14.97% to RMB 7,549,067,883.79 as of September 30, 2014, compared to RMB 6,566,006,124.91 at the end of the previous year[7] - Total liabilities increased significantly, with accounts payable rising by 30.79% to RMB 570,187,348.43 as of September 30, 2014, driven by increased procurement due to sales growth[16] - Short-term borrowings increased by 37.99% to RMB 677,630,963.80 as of September 30, 2014, reflecting an increase in borrowed funds[16] Cash Flow and Investments - The company reported a net cash flow from operating activities of RMB 394,417,154.21 for the year-to-date period[7] - Cash received from tax refunds increased by 110.73% to RMB 26,662,818.24 in the first nine months of 2014, primarily due to higher export tax refunds[18] - Cash received from investment increased to ¥98 million, a 100% increase compared to ¥49 million in the previous period[19] - Cash paid for debt repayment decreased by 40.02% to ¥595 million from ¥992 million, primarily due to reduced loan repayments[19] - The company’s total investment in securities at the end of the reporting period was RMB 9,562,427.38, with a loss of RMB 981,671.44 reported[24] Shareholder Information - The total number of shareholders at the end of the reporting period was 8,738, including 3 H-share shareholders[12] - The largest shareholder, Hong Kong Central Clearing (Agent), held 37.87% of the shares, amounting to 111,992,454 shares[12] - Health元药业集团股份有限公司, the second-largest shareholder, owned 26.21% of the shares, totaling 77,510,167 shares[12] - The total number of shares held by the company at the end of the reporting period was 1,619,573, with a book value of RMB 9,562,427.38[24] Operational Costs - Operating costs for Q3 2014 were RMB 575,416,418.40, up 61.78% from RMB 355,685,496.77 in Q3 2013, primarily due to increased sales and changes in product sales structure[17] - Financial expenses surged by 1214.54% to RMB 1,693,331.98 in Q3 2014, primarily due to increased borrowings and exchange rate fluctuations[17] Non-Operating Income - The company reported a 143.69% increase in non-operating income to RMB 37,996,852.32 in Q3 2014, mainly from government subsidies[17] - Investment income decreased by 86.63% to RMB 96,766.34 in Q3 2014, mainly due to reduced investment income from joint ventures[17] Compliance and Regulations - The company has committed to comply with the Hong Kong Stock Exchange regulations regarding the sale of shares, ensuring no sales occur within the first six months post-listing[22] - The company has committed to adhering to the guidelines set by the China Securities Regulatory Commission regarding the transfer of restricted shares[22] - The company plans to disclose any significant share reductions (over 5%) two trading days prior to the first sale[23] Engagement with Investors - The company has been actively engaging with institutional investors to discuss its operational performance and future development strategies[27]